Molecular Quality Controls Market is anticipated to exceed US$ 408 million by 2033, at a CAGR of 7.2% | FMI

According to FMI’s most recent market research, the global Molecular Quality Controls Market is anticipated to be worth US$ 204 million in 2023. During the projection period, the market is estimated to grow at a 7.2% CAGR. The estimate is expected to exceed US$ 408 million by 2033.

The rising adoption of third-party quality controls, the growing number of accredited clinical laboratories, the rising demand for external quality assessment support, increasing government funding to support genomics projects, increasing demand for personalized medicines, declining sequencing costs, and the rising prevalence of infectious diseases, cancer, and genetic diseases are all driving molecular quality controls market forward.

The COVID-19 pandemic had a detrimental impact on molecular quality controls sales. As governments increasingly loosen their prohibitions on migration, there is a rise in testing numbers.

For More Insights on this Market, Get A Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14301

Due to the expanding global burden of various diseases, the number of laboratory tests performed has grown. The number of laboratories in both the public and private sectors is growing to satisfy this need.

Setting up a quality control process in a clinical laboratory necessitates a large financial commitment. Laboratories must also have specialized people to supervise the quality control system.

Regardless of the number of tests completed, QC procedures entail equal expenses. As a result, the expense of implementing QC processes in clinical laboratories that perform modest quantities of diagnostic tests is prohibitively expensive. This, along with funding restrictions in many hospitals and laboratories in both developed and emerging economies, is projected to lead to a decreased adoption of quality-control techniques.

QC materials for molecular assays are samples or materials used to assess the performance and reliability of molecular assays, such as PCR (polymerase chain reaction), sequencing, and other nucleic acid-based tests. These controls are used to ensure the accuracy, precision, and sensitivity of the test results.

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-14301

New multi-analyte and multi-instrument controls have been developed as a result of technological improvements. These cutting-edge controls combine many instrument-specific controls into a single control, allowing clinical laboratories to save money. In addition, these controls save time by eliminating the need for separate QC processes for each analyte.

In the next years, the increased availability of such molecular quality controls for infectious disease diagnostics and other applications is likely to drive market expansion.

Key Takeaways:

  • The Asia Pacific molecular quality controls market is expected to reach US$ 72.07 million in 2028 from US$ 34.27 million in 2021; it is estimated to grow at a CAGR of 11.2%.
  • The European molecular quality controls market is expected to reach US$ 109.59 million by 2028 from US$ 55.76 million in 2021; it is estimated to grow at a CAGR of 10.1%.
  • The growing implementation of genomic sequencing in healthcare systems is supported by substantial government investments, totaling over US$ 4 billion by at least 14 countries.

To Buy this Report Visit @ https://www.futuremarketinsights.com/checkout/14301

Key developments in the market:

  • Abbott got FDA clearance for NAVIATOR, a next-generation TAVI device designed to treat aortic stenosis, in January 2023.
  • LGC’s new state-of-the-art location in Oxford began providing crucial diagnostics solutions and research in September 2022.

Dominant players in the market are:

  • LGC
  • Abbott
  • Microbiologics, Inc.

Molecular Quality Controls Market Segmentation

By Analyte:

  • Single-analyte Controls
  • Multi-analyte Controls

By Product Type:

  • Independent controls
  • Instrument-specific controls

By Application:

  • Infectious Diseases Diagnostics
  • Oncology Testing and Genetic testing

By End User:

  • Diagnostic laboratories
  • Hospitals
  • IVD manufacturers & CROs
  • Academic & Research Institutes

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these